Week in Review: Korea's Samsung BioLogics Files for $2.5 Billion IPO

Samsung BioLogics, a biosimilar CMO, filed for a South Korean IPO that will raise between $1.8 and $2.7 billion at a $9 billion valuation; Bio-Techne of the US acquired fellow lab toolmaker Advanced Cell Diagnostics in a $325 million deal; Neusoft Xikang Healthcare raised $64 million to support its China online healthcare operations; Bristol-Myers Squibb will reacquire the rights to a cancer drug candidate from Singapore's ASLAN Pharma in a $60 million deal; Maxhealth Medicine, which distributes high-tech medical devices in China, invested $1.3 million in the UK's Rex Bionics; Zhejiang Hisun Pharma expanded its oncology partnership with US-based Celsion to include a cancer immunotherapy; ScinoPharm Taiwan will collaborate with CVie Therapeutics, also of Taiwan, to discover a heart failure drug; Magellan Diagnostics, a Boston area medical device company, received CFDA clearance for China marketing of a system that measures the level of lead in the blood; CANbridge Life Sciences, a Beijing in-licensing pharma, signed up Boehringer Ingelheim China to manufacture its development stage HER-3 cancer drug; and Shanghai SynTheAll Pharma (STA), WuXi AppTec's small-molecule process development and manufacturing subsidiary, is opening a San Diego site. More details.... Stock Symbols: (NSDQ: TECH) (NYSE: BMY) (LON: RXB) (SHA: 600267) (NSDQ: CLSN) (TWSE: 1789) Share this with colleagues: // //